Pathios Therapeutics
Oxford, GB · Founded 2017 · 20 employees on LinkedIn · 1 known investors
Pathios Therapeutics is a drug discovery and development company working on small-molecule drugs that block the immune cell receptor GPR65, which senses the acidic tumor microenvironment, with a lead asset (PTT-4256) aimed at treating solid cancers. The company targets cancer immunotherapy applications across a broad range of solid tumors.
Founders & leadership
Pathios Therapeutics was founded in 2017 by Alan Naylor.
Investors · 1
Competitors · 3
by search overlapPathos22 shared keywordsPathos applies AI, biological modeling, and a large collection of multimodal oncology patient data to develop cancer drugs and accelerate clinical development. It operates the PathOS platform with engines for asset selection, clinical trial execution, and an oncology foundation model.
Bioworld15 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Artios Pharma14 shared keywordsArtios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers. The company focuses on advancing DDR-based therapies through strategic partnerships.
Companies competing with Pathios Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Companies House · registry record
View on Companies House ↗- Registered name
- PATHIOS THERAPEUTICS LIMITED
- Company number
- 10641754
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 27 Feb 2017
- Registered office
- 99 Park Drive, Milton, Abingdon, OX14 4RY
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Dec 2025 · next due 30 Sept 2027
- Confirmation statement
- last made up to 26 Feb 2026 · next due 12 Mar 2027
Current officers · 6
- Samantha Ann Harris — secretary, appointed 15 Jun 2022
- Brenton Karl Ahrens — director, appointed 28 Aug 2019
- Paul Grant Higham — director, appointed 7 Jun 2024
- Thomas David Mccarthy — director, appointed 27 Feb 2017
- Christopher Dean Nave — director, appointed 9 Sept 2019
- Jon Wigginton — director, appointed 14 Jul 2025
Source: Companies House public register · retrieved 16 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Pathios Therapeutics do?
- Pathios Therapeutics is a drug discovery and development company working on small-molecule drugs that block the immune cell receptor GPR65, which senses the acidic tumor microenvironment, with a lead asset (PTT-4256) aimed at treating solid cancers. The company targets cancer immunotherapy applications across a broad range of solid tumors.
- Who founded Pathios Therapeutics?
- Pathios Therapeutics was founded by Alan Naylor in 2017.
- Who are Pathios Therapeutics's investors?
- Pathios Therapeutics's investors include Canaan Partners.
- Where is Pathios Therapeutics headquartered?
- Pathios Therapeutics is headquartered in Oxford, GB.